At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Not Yet Opened 02-02 16:00:00 EST
344.68
+2.80
+0.82%
盘后344.40
-0.28-0.08%
19:56 EST
High345.98Low339.41Vol1.90M
Open339.47D1 Closing341.88Amplitude1.92%
Mkt Cap185.60BTradable Cap185.09BTotal Shares538.48M
T/O654.17MT/O Rate0.35%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

TRADING DAY-Solid data over hard assets
Reuters  ·  06:00
TRADING DAY-Solid data over hard assets
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN)
TIPRANKS  ·  02-02 21:01
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN)
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  02-02 19:00
Calendar of U.S. Earnings Expected in the Week Ahead
Assessing Amgen (AMGN) Valuation After Recent Share Price Momentum And Pipeline Expectations
Simply Wall St.  ·  02-01 17:25
Assessing Amgen (AMGN) Valuation After Recent Share Price Momentum And Pipeline Expectations
Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities
Simply Wall St.  ·  01-31 16:39
Amgen Lawsuit And Eczema Drug Exit Reframe Risk And R&D Priorities
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Amgen (AMGN) and Indivior (INDV)
TIPRANKS  ·  01-31
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Amgen (AMGN) and Indivior (INDV)
Amgen to Terminate License, Collaboration Agreement With Kyowa Kirin for Rocatinlimab
MT Newswires Live  ·  01-30
Amgen to Terminate License, Collaboration Agreement With Kyowa Kirin for Rocatinlimab
Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration
Dow Jones  ·  01-30
Amgen, Kyowa Kirin Ending Atopic Dermatitis Drug Collaboration
Amgen Inc -Co and Kyowa Kirin Terminate License and Collaboration Agreement - SEC Filing
THOMSON REUTERS  ·  01-30
Amgen Inc -Co and Kyowa Kirin Terminate License and Collaboration Agreement - SEC Filing
Amgen Inc - Enters Termination Agreement With Kyowa Kirin - SEC Filing
THOMSON REUTERS  ·  01-30
Amgen Inc - Enters Termination Agreement With Kyowa Kirin - SEC Filing
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Reuters  ·  01-30
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
Oppenheimer Raises Price Target on Amgen to $400 From $380, Keeps Outperform Rating
MT Newswires Live  ·  01-29
Oppenheimer Raises Price Target on Amgen to $400 From $380, Keeps Outperform Rating
Amgen price target raised to $400 from $380 at Oppenheimer
TIPRANKS  ·  01-29
Amgen price target raised to $400 from $380 at Oppenheimer
Amgen Inc. to Report Fourth Quarter and Full Year Financial Results
Reuters  ·  01-29
Amgen Inc. to Report Fourth Quarter and Full Year Financial Results
Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com
Dow Jones  ·  01-29
Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com
Amgen Advances Teprotumumab Program With Completed Phase 1 Study in Healthy Chinese Volunteers
TIPRANKS  ·  01-28
Amgen Advances Teprotumumab Program With Completed Phase 1 Study in Healthy Chinese Volunteers
Citi Reaffirms Their Hold Rating on Amgen (AMGN)
TIPRANKS  ·  01-27
Citi Reaffirms Their Hold Rating on Amgen (AMGN)
Amgen Is Maintained at Buy by UBS
Dow Jones  ·  01-27
Amgen Is Maintained at Buy by UBS
UBS Adjusts Price Target on Amgen to $390 From $380, Maintains Buy Rating
MT Newswires Live  ·  01-26
UBS Adjusts Price Target on Amgen to $390 From $380, Maintains Buy Rating
Amgen Inc : UBS Raises Target Price to $390 From $380
THOMSON REUTERS  ·  01-26
Amgen Inc : UBS Raises Target Price to $390 From $380

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--